Refractory ALK-Positive Anaplastic Large Cell Lymphoma: Long Term Survival with Crizotinib

類似資料

• DA-EPOCH-R in Aggressive CD 20 Positive B Cell Lymphomas: Real-World Experience
  著者:: Ganesan, Prasanth, 等
  出版事項: (2017)
• Primary B-cell lymphoblastic lymphoma of the ovary
  著者:: Anjana Joel, 等
  出版事項: (2018-01-01)
• Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
  著者:: Carolina Valeria Mahuad, 等
  出版事項: (2016-06-01)
• Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib
  著者:: Mahuad, Carolina Valeria, 等
  出版事項: (2016)
• Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
  著者:: Mitou, Géraldine, 等
  出版事項: (2015)